Want to see CTKB full AI Analyst Report?
CTKB Stock Chart & Stats
$4.61
-$0.08(-1.16%)
At close: 4:00 PM EST
$4.61
-$0.08(-1.16%)
Day’s Range― - ―
52-Week Range$3.09 - $6.18
Previous CloseN/A
Volume141.86K
Average Volume (3M)1.83M
Market Cap
$572.10M
Enterprise Value$484.65M
Total Cash (Recent Filing)$262.23M
Total Debt (Recent Filing)$36.33M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding129,142,600
10 Day Avg. Volume3,347,127
30 Day Avg. Volume1,833,508
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.89
Price to Sales (P/S)3.20
P/FCF Ratio-73.56
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue2.37
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda-21.88
Forecast
1Y Price Target
$5.69Price Target Upside23.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$208.83M
Bulls Say, Bears Say
Bulls Say
Market LeadershipCytek remains a leader in the flow cytometry market and continues to take share.
Product LaunchThe company launched a new instrument, the Cytek Aurora Evo system, which offers improvements relative to their flagship Aurora, and feedback has been positive.
Revenue GrowthRecurring revenue maintained positive momentum, with both services and consumables growing 18% year over year.
Bears Say
Geopolitical And Economic HeadwindsMultiple ongoing headwinds, such as NIH budgets, China, tariffs, and biopharma funding, continue to impact revenues and margins this year.
Market ContractionRecent spending trends suggest the flow cytometry market itself may be contracting or at least stagnating.
Uncertain Growth PathThe path back to growth remains uncertain as does the potential timeline for when the CapEx cycle will reinvigorate organic growth.
Cytek Biosciences News
CTKB FAQ
What was Cytek Biosciences, Inc.’s price range in the past 12 months?
Cytek Biosciences, Inc. lowest stock price was $3.09 and its highest was $6.18 in the past 12 months.
What is Cytek Biosciences, Inc.’s market cap?
Cytek Biosciences, Inc.’s market cap is $572.10M.
When is Cytek Biosciences, Inc.’s upcoming earnings report date?
Cytek Biosciences, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 41 days.
How were Cytek Biosciences, Inc.’s earnings last quarter?
Cytek Biosciences, Inc. released its earnings results on May 07, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.092 by -$0.058.
Is Cytek Biosciences, Inc. overvalued?
According to Wall Street analysts Cytek Biosciences, Inc.’s price is currently Undervalued.
Does Cytek Biosciences, Inc. pay dividends?
Cytek Biosciences, Inc. does not currently pay dividends.
What is Cytek Biosciences, Inc.’s EPS estimate?
Cytek Biosciences, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Cytek Biosciences, Inc. have?
Cytek Biosciences, Inc. has 129,142,600 shares outstanding.
What happened to Cytek Biosciences, Inc.’s price movement after its last earnings report?
Cytek Biosciences, Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.092. Following the earnings report the stock price went down -6.301%.
Which hedge fund is a major shareholder of Cytek Biosciences, Inc.?
Currently, no hedge funds are holding shares in CTKB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytek Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.69 (23.37% Upside)
$5.69 (23.37% Upside)
Blogger Sentiment
Bullish
CTKB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 50.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.29%
12-Months-Change
Fundamentals
Return on Equity
-20.77%
Trailing 12-Months
Asset Growth
-6.94%
Trailing 12-Months
Company Description
Cytek Biosciences, Inc.
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
CTKB Company Deck
CTKB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of constructive commercial momentum—led by a strong U.S. rebound, double-digit growth in recurring revenue, robust installed base expansion and growing cloud/user engagement—while also disclosing near-term profitability pressures from higher operating and legal expenses, regional disruption (EMEA) and APAC order timing. Management reaffirmed full-year guidance and expects adjusted EBITDA to turn positive for 2026, supported by a strong balance sheet.View all CTKB earnings summariesCTKB Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$5.69
▲(23.37% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
8.42% Insiders
13.14% Mutual Funds
15.22% Other Institutional Investors
51.59% Public Companies and
Individual Investors










